Company intelligence / Profile preview
AdcoTx
London, England, United Kingdomadcotx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
AdcoTx is a pre-clinical stage biotechnology company translating oncology research from the University of Cambridge into novel therapeutics. The company is developing an antibody-drug conjugate (ADC) targeting LGR5, a well-validated marker associated with tumor growth, to improve first-line treatment options for colorectal cancer patients worldwide. AdcoTx's lead program has demonstrated in vivo proof of principle, showing selective activity against tumor cells. The company operates as a virtual biotech and is focused on advancing its lead asset toward a Phase I clinical trial.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugateBiologic
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on AdcoTx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AdcoTx.